Dyne Therapeutics (DYN) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Arcus Biosciences (RCUS) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 74.8% versus a gain of 14.5%. Over five years, DYN leads with a +7.3% price change compared with -28.7% for RCUS. Arcus Biosciences is the larger company by market cap ($3.08 billion vs $2.98 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | RCUS |
|---|---|---|
| Share price | $15.97 | $24.52 |
| Market cap | $2.98B | $3.08B |
| 1-day change | +3.70% | +0.99% |
| YTD return | -18.35% | +2.90% |
| 1-year return | +14.48% | +74.77% |
| 5-year return | +7.33% | -28.70% |
| EPS (TTM) | $-3.30 | $-3.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.31 | $31.74 |
| 52-week low | $13.73 | $14.26 |
| Distance from 52-week high | -41.51% | -22.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +125.42% | +62.77% |
| Average volume | 2.77M | 1.32M |
| Shares outstanding | 186.75M | 125.77M |
| Employees | 289 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCUS has outperformed DYN by 60.3 percentage points over the past year.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
DYN vs RCUS FAQ
Which is bigger, Dyne Therapeutics or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $3.08B compared with $2.98B for Dyne Therapeutics (DYN).
Which stock has performed better over the past year, DYN or RCUS?
RCUS returned +74.77% over the past 12 months, compared with +14.48% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.